Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice

Translational Stroke Research

Volumn 7, Issue 6, 2016, Pages 535-547

  Yao, Yang ^a   Miao, Weimin ^b   Liu, Zhijia ^a   Han, Wei ^a   Shi, Kaibin ^a   Shen, Yi ^a   Li, Handong ^a   Liu, Qiang ^a,c   Fu, Ying ^a   Huang, DeRen ^d   Shi, Fu Dong ^a,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

^d Neurology and Neuroscience Associates   (United States)

Author keywords

Dimethyl fumarate; HO 1; Monomethyl fumarate; Nrf2; Stroke

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID METHYL ESTER; TRANSCRIPTION FACTOR NRF2; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; CITRACONIC ACID; FUMARIC ACID DERIVATIVE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE; IMMUNOSUPPRESSIVE AGENT; MALEIC ACID DERIVATIVE; MALONALDEHYDE; NEUROPROTECTIVE AGENT; NFE2L2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN EDEMA; BRAIN ISCHEMIA; BRAIN TISSUE; CELL DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; CONTROLLED STUDY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY; TREATMENT DURATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CONVALESCENCE; DEFICIENCY; DIAGNOSTIC IMAGING; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; INFARCTION, MIDDLE CEREBRAL ARTERY; METABOLISM; NEUROLOGIC EXAMINATION; TIME FACTOR;

ANIMALS; BRAIN EDEMA; CALCIUM-BINDING PROTEINS; DIMETHYL FUMARATE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FUMARATES; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE; IMMUNOSUPPRESSIVE AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALEATES; MALONDIALDEHYDE; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; NEUROLOGIC EXAMINATION; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; RECOVERY OF FUNCTION; REPERFUSION INJURY; TIME FACTORS;

EID: 84986329588     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-016-0496-0     Document Type: Article

References (72)

1. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383(9913):245–54.
2. Sun N, Keep RF, Hua Y, Xi G. Critical role of the sphingolipid pathway in stroke: a review of current utility and potential therapeutic targets. Transl Stroke Res. 2016. doi:10.1007/s12975-016-0477-3
3. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368(10):893–903. doi:10.1056/NEJMoa1214300.
4. Grotta JC, Hacke W. Stroke neurologist’s perspective on the new endovascular trials. Stroke. 2015;46(6):1447–52. doi:10.1161/STROKEAHA.115.008384.
5. Pundik S, Xu K, Sundararajan S. Reperfusion brain injury: focus on cellular bioenergetics. Neurology. 2012;79(13 Suppl 1):S44–51. doi:10.1212/WNL.0b013e3182695a14.
6. Ahnstedt H, Sweet J, Cruden P, Bishop N, Cipolla MJ. Effects of early post-ischemic reperfusion and tPA on cerebrovascular function and nitrosative stress in female rats. Transl Stroke Res. 2016;7(3):228–38. doi:10.1007/s12975-016-0468-4.
7. Liesz A, Kleinschnitz C. Regulatory T cells in post-stroke immune homeostasis. Transl Stroke Res. 2016;7(4):313–21. doi:10.1007/s12975-016-0465-7.
8. Nakata M, Nakagomi T, Maeda M, Nakano-Doi A, Momota Y, Matsuyama T. Induction of perivascular neural stem cells and possible contribution to neurogenesis following transient brain ischemia/reperfusion injury. Transl Stroke Res. 2016. doi:10.1007/s12975-016-0479-1.
9. Margaill I, Plotkine M, Lerouet D. Antioxidant strategies in the treatment of stroke. Free Radic Biol Med. 2005;39(4):429–43. doi:10.1016/j.freeradbiomed.2005.05.003.
10. Amaro S, Chamorro A. Translational stroke research of the combination of thrombolysis and antioxidant therapy. Stroke. 2011;42(5):1495–9. doi:10.1161/STROKEAHA.111.615039.
11. Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke. 2008;39(6):1751–8. doi:10.1161/STROKEAHA.107.503334.
12. Macleod MR, van der Worp HB, Sena ES, Howells DW, Dirnagl U, Donnan GA. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke. 2008;39(10):2824–9. doi:10.1161/STROKEAHA.108.515957.
13. Kahles T, Brandes RP. NADPH oxidases as therapeutic targets in ischemic stroke. Cell Mol Life Sci. 2012;69(14):2345–63. doi:10.1007/s00018-012-1011-8.
14. Moretti A, Ferrari F, Villa RF. Neuroprotection for ischaemic stroke: current status and challenges. Pharmacol Ther. 2015;146:23–34. doi:10.1016/j.pharmthera.2014.09.003.
15. Kent TA, Mandava P. Embracing biological and methodological variance in a new approach to pre-clinical stroke testing. Transl Stroke Res. 2016;7(4):274–83. doi:10.1007/s12975-016-0463-9.
16. Salmen A, Gold R. Mode of action and clinical studies with fumarates in multiple sclerosis. Exp Neurol. 2014;262 Pt A:52–6. doi:10.1016/j.expneurol.2014.02.015.
17. Ohl K, Tenbrock K, Kipp M. Oxidative stress in multiple sclerosis: central and peripheral mode of action. Exp Neurol. 2015. doi:10.1016/j.expneurol.2015.11.010.
18. Kastrati I, Siklos MA, Calderon-Gierszal EL, El-Shennawy L, Georgieva G, Thayer EN et al. Dimethyl fumarate inhibits the nuclear factor kappaB pathway in breast cancer cells by covalent modification of p65. J Biol Chem. 2015. doi:10.1074/jbc.M115.679704
19. Jing X, Shi H, Zhang C, Ren M, Han M, Wei X, et al. Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson’s disease by enhancing Nrf2 activity. Neuroscience. 2015;286:131–40. doi:10.1016/j.neuroscience.2014.11.047.
20. Zhao X, Sun G, Zhang J, Ting SM, Gonzales N, Aronowski J. Dimethyl fumarate protects brain from damage produced by intracerebral hemorrhage by mechanism involving Nrf2. Stroke. 2015;46(7):1923–8. doi:10.1161/STROKEAHA.115.009398.
21. Iniaghe LO, Krafft PR, Klebe DW, Omogbai EK, Zhang JH, Tang J. Dimethyl fumarate confers neuroprotection by casein kinase 2 phosphorylation of Nrf2 in murine intracerebral hemorrhage. Neurobiol Dis. 2015;82:349–58. doi:10.1016/j.nbd.2015.07.001.
22. Kunze R, Urrutia A, Hoffmann A, Liu H, Helluy X, Pham M, et al. Dimethyl fumarate attenuates cerebral edema formation by protecting the blood-brain barrier integrity. Exp Neurol. 2015;266:99–111. doi:10.1016/j.expneurol.2015.02.022.
23. Gillard GO, Collette B, Anderson J, Chao J, Scannevin RH, Huss DJ, et al. DMF, but not other fumarates, inhibits NF-kappaB activity in vitro in an Nrf2-independent manner. J Neuroimmunol. 2015;283:74–85. doi:10.1016/j.jneuroim.2015.04.006.
24. Wallbrecht K, Drick N, Hund AC, Schon MP. Downregulation of endothelial adhesion molecules by dimethylfumarate, but not monomethylfumarate, and impairment of dynamic lymphocyte-endothelial cell interactions. Exp Dermatol. 2011;20(12):980–5. doi:10.1111/j.1600-0625.2011.01376.x.
25. Skoko JJ, Wakabayashi N, Noda K, Kimura S, Tobita K, Shigemura N, et al. Loss of Nrf2 in mice evokes a congenital intrahepatic shunt that alters hepatic oxygen and protein expression gradients and toxicity. Toxicol Sci. 2014;141(1):112–9. doi:10.1093/toxsci/kfu109.
26. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20(1):84–91.
27. Gan Y, Liu Q, Wu W, Yin JX, Bai XF, Shen R, et al. Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc Natl Acad Sci U S A. 2014;111(7):2704–9. doi:10.1073/pnas.1315943111.
28. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372(9648):1463–72. doi:10.1016/S0140-6736(08)61619-0.
29. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–107. doi:10.1056/NEJMoa1114287.
30. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–97. doi:10.1056/NEJMoa1206328.
31. Liu Q, Tang Z, Gan Y, Wu W, Kousari A, La Cava A, et al. Genetic deficiency of beta2-containing nicotinic receptors attenuates brain injury in ischemic stroke. Neuroscience. 2014;256:170–7. doi:10.1016/j.neuroscience.2013.10.049.
32. Liu H, Wang Y, Xiao Y, Hua Z, Cheng J, Jia J. Hydrogen sulfide attenuates tissue plasminogen activator-induced cerebral hemorrhage following experimental stroke. Transl Stroke Res. 2016;7(3):209–19. doi:10.1007/s12975-016-0459-5.
33. Liu Y, Tang G, Li Y, Wang Y, Chen X, Gu X, et al. Metformin attenuates blood-brain barrier disruption in mice following middle cerebral artery occlusion. J Neuroinflammation. 2014;11:177. doi:10.1186/s12974-014-0177-4.
34. Zhao P, Zhou R, Zhu XY, Hao YJ, Li N, Wang J, et al. Matrine attenuates focal cerebral ischemic injury by improving antioxidant activity and inhibiting apoptosis in mice. Int J Mol Med. 2015;36(3):633–44. doi:10.3892/ijmm.2015.2260.
35. Hua K, Sheng X, Li TT, Wang LN, Zhang YH, Huang ZJ, et al. The edaravone and 3-n-butylphthalide ring-opening derivative 10b effectively attenuates cerebral ischemia injury in rats. Acta Pharmacol Sin. 2015;36(8):917–27. doi:10.1038/aps.2015.31.
36. Lee CH, Yoo KY, Choi JH, Park OK, Hwang IK, Kim SK, et al. Neuronal damage is much delayed and microgliosis is more severe in the aged hippocampus induced by transient cerebral ischemia compared to the adult hippocampus. J Neurol Sci. 2010;294(1-2):1–6. doi:10.1016/j.jns.2010.04.014.
37. Yaidikar L, Thakur S. Arjunolic acid, a pentacyclic triterpenoidal saponin of Terminalia arjuna bark protects neurons from oxidative stress associated damage in focal cerebral ischemia and reperfusion. Pharmacol Rep. 2015;67(5):890–5. doi:10.1016/j.pharep.2015.02.003.
38. Ekici F, Karson A, Dillioglugil MO, Gurol G, Kir HM, Ates N. The effects of vagal nerve stimulation in focal cerebral ischemia and reperfusion model. Turk Neurosurg. 2013;23(4):451–7. doi:10.5137/1019-5149.JTN.7114-12.1.
39. Kappos L, Giovannoni G, Gold R, Phillips JT, Arnold DL, Hotermans C, et al. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis. Eur J Neurol. 2015;22(4):664–71. doi:10.1111/ene.12624.
40. English C, Aloi JJ. New FDA-approved disease-modifying therapies for multiple sclerosis. Clin Ther. 2015;37(4):691–715. doi:10.1016/j.clinthera.2015.03.001.
41. Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. J Med Econ. 2015:1-36. doi:10.3111/13696998.2015.1135805.
42. Chen H, Assmann JC, Krenz A, Rahman M, Grimm M, Karsten CM, et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. J Clin Invest. 2014;124(5):2188–92. doi:10.1172/JCI72151.
43. Milenkovic M, Arsenovic-Ranin N, Vucicevic D, Bufan B, Jancic I, Stojic-Vukanic Z. Beneficial effects of dimethyl fumarate on experimental autoimmune myocarditis. Arch Med Res. 2008;39(7):639–46. doi:10.1016/j.arcmed.2008.07.003.
44. Robles L, Vaziri ND, Li S, Takasu C, Masuda Y, Vo K, et al. Dimethyl fumarate ameliorates acute pancreatitis in rodent. Pancreas. 2015;44(3):441–7. doi:10.1097/MPA.0000000000000275.
45. Robles L, Vaziri ND, Li S, Masuda Y, Takasu C, Takasu M, et al. Dimethyl fumarate protects pancreatic islet cells and non-endocrine tissue in L-arginine-induced chronic pancreatitis. PLoS One. 2014;9(9):e107111. doi:10.1371/journal.pone.0107111.
46. Dibbert S, Clement B, Skak-Nielsen T, Mrowietz U, Rostami-Yazdi M. Detection of fumarate-glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism. Arch Dermatol Res. 2013;305(5):447–51. doi:10.1007/s00403-013-1332-y.
47. Lehmann JC, Listopad JJ, Rentzsch CU, Igney FH, von Bonin A, Hennekes HH, et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol. 2007;127(4):835–45. doi:10.1038/sj.jid.5700686.
48. Koh SH, Park HH. Neurogenesis in stroke recovery. Transl Stroke Res. 2016. doi:10.1007/s12975-016-0460-z
49. Hanson J, Gille A, Zwykiel S, Lukasova M, Clausen BE, Ahmed K, et al. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest. 2010;120(8):2910–9. doi:10.1172/JCI42273.
50. Digby JE, Martinez F, Jefferson A, Ruparelia N, Chai J, Wamil M, et al. Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arterioscler Thromb Vasc Biol. 2012;32(3):669–76. doi:10.1161/ATVBAHA.111.241836.
51. Hanson J, Gille A, Offermanns S. Role of HCA(2) (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin. Pharmacol Ther. 2012;136(1):1–7. doi:10.1016/j.pharmthera.2012.06.003.
52. Rahman M, Muhammad S, Khan MA, Chen H, Ridder DA, Muller-Fielitz H, et al. The beta-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nat Commun. 2014;5:3944. doi:10.1038/ncomms4944.
53. Becker KJ. Strain-related differences in the immune response: relevance to human stroke. Transl Stroke Res. 2016;7(4):303–12. doi:10.1007/s12975-016-0455-9.
54. Yamasaki Y, Matsuo Y, Matsuura N, Onodera H, Itoyama Y, Kogure K. Transient increase of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, in ischemic brain areas after focal ischemia in rats. Stroke. 1995;26(2):318–22. discussion 22-3.
55. Ding Y, Chen M, Wang M, Li Y, Wen A. Posttreatment with 11-keto-beta-boswellic acid ameliorates cerebral ischemia-reperfusion injury: Nrf2/HO-1 pathway as a potential mechanism. Mol Neurobiol. 2015;52(3):1430–9. doi:10.1007/s12035-014-8929-9.
56. Sun J, Ren X, Simpkins JW. Sequential upregulation of superoxide dismutase 2 and heme oxygenase 1 by tert-butylhydroquinone protects mitochondria during oxidative stress. Mol Pharmacol. 2015;88(3):437–49. doi:10.1124/mol.115.098269.
57. Han J, Wang M, Jing X, Shi H, Ren M, Lou H. (-)-Epigallocatechin gallate protects against cerebral ischemia-induced oxidative stress via Nrf2/ARE signaling. Neurochem Res. 2014;39(7):1292–9. doi:10.1007/s11064-014-1311-5.
58. Shi H, Jing X, Wei X, Perez RG, Ren M, Zhang X, et al. S-allyl cysteine activates the Nrf2-dependent antioxidant response and protects neurons against ischemic injury in vitro and in vivo. J Neurochem. 2015;133(2):298–308. doi:10.1111/jnc.12986.
59. Chen S, Yang Q, Chen G, Zhang JH. An update on inflammation in the acute phase of intracerebral hemorrhage. Transl Stroke Res. 2015;6(1):4–8. doi:10.1007/s12975-014-0384-4.
60. Sagai M, Tin Win-Shwe T. Oxidative stress derived from airborne fine and ultrafine particles and the effects on brain-nervous system: part 2. Nihon Eiseigaku Zasshi. 2015;70(3):220–9. doi:10.1265/jjh.70.220.
61. Alhadidi Q, Bin Sayeed MS, Shah ZA. Cofilin as a promising therapeutic target for ischemic and hemorrhagic stroke. Transl Stroke Res. 2016;7(1):33–41. doi:10.1007/s12975-015-0438-2.
62. Husain K, Hernandez W, Ansari RA, Ferder L. Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem. 2015;6(3):209–17. doi:10.4331/wjbc.v6.i3.209.
63. Huang Y, Li W, Su ZY, Kong AT. The complexity of the Nrf2 pathway: beyond the antioxidant response. J Nutr Biochem. 2015. doi:10.1016/j.jnutbio.2015.08.001.
64. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, et al. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354(6):588–600. doi:10.1056/NEJMoa052980.
65. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357(6):562–71. doi:10.1056/NEJMoa070240.
66. Bath PM, Gray LJ, Bath AJ, Buchan A, Miyata T, Green AR, et al. Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol. 2009;157(7):1157–71. doi:10.1111/j.1476-5381.2009.00196.x.
67. Kaste M, Murayama S, Ford GA, Dippel DW, Walters MR, Tatlisumak T, et al. Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. Cerebrovasc Dis. 2013;36(3):196–204. doi:10.1159/000353680.
68. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134(Pt 3):678–92. doi:10.1093/brain/awq386.
69. Kobayashi EH, Suzuki T, Funayama R, Nagashima T, Hayashi M, Sekine H, et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun. 2016;7:11624. doi:10.1038/ncomms11624.
70. Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, Spencer CM, Shetty A, Sagan SA, et al. Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci U S A. 2016;113(17):4777–82. doi:10.1073/pnas.1603907113.
71. Adam J, Hatipoglu E, O’Flaherty L, Ternette N, Sahgal N, Lockstone H, et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell. 2011;20(4):524–37. doi:10.1016/j.ccr.2011.09.006.
72. Ooi A, Wong JC, Petillo D, Roossien D, Perrier-Trudova V, Whitten D, et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell. 2011;20(4):511–23. doi:10.1016/j.ccr.2011.08.024.